Following these proceedings, H.C. Wainwright initiated its ProPhase Labs Inc [PRPH] rating to a Buy in a research note published on December 20, 2021; the price target was $12. A number of analysts have revised their coverage, including Dawson James’s analysts, who decreased its forecast for the stock in mid October from “a Buy” to “a Neutral”. Dawson James began covering PRPH with “Buy” recommendation on January 20, 2021.
Price Performance Review of PRPH
On Tuesday, ProPhase Labs Inc [NASDAQ:PRPH] saw its stock jump 13.25% to $0.35. Over the last five days, the stock has gained 16.52%. ProPhase Labs Inc shares have fallen nearly -53.60% since the year began. Nevertheless, the stocks have fallen -93.54% over the past one year. While a 52-week high of $5.62 was reached on 01/03/25, a 52-week low of $0.22 was recorded on 02/03/25. SMA at 50 days reached $0.3841, while 200 days put it at $1.4528.
Levels Of Support And Resistance For PRPH Stock
The 24-hour chart illustrates a support level at 0.3067, which if violated will result in even more drops to 0.2633. On the upside, there is a resistance level at 0.3767. A further resistance level may holdings at 0.4033. The Relative Strength Index (RSI) on the 14-day chart is 51.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0173, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.67%. Stochastics %K at 32.03% indicates the stock is a holding.
How much short interest is there in ProPhase Labs Inc?
A steep rise in short interest was recorded in ProPhase Labs Inc stocks on 2025-03-31, dropping by -0.47 million shares to a total of 1.19 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 1.66 million shares. There was a decline of -39.81%, which implies that there is a negative sentiment for the stock.
